Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(25.0%)
Phase 4
1(25.0%)
Phase 1
1(25.0%)
Phase 3
1(25.0%)
4Total
N/A(1)
Phase 4(1)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03990181Not ApplicableCompleted

Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement

Role: collaborator

NCT02033122Phase 3Unknown

Effect of Aerobic Training in Moderate or Severe Asthmatic Patients

Role: lead

NCT01584115Phase 1Unknown

Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)

Role: lead

NCT01584687Phase 4Unknown

mRNA Expression as a Biomarker of Omalizumab Response

Role: lead

All 4 trials loaded